Selpercatinib

From China Leadership to Global Premier: Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2025 annual results and long-term strategic blueprint. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "2025 marks the most successful year in Innovent's history. We achieved historic breakthroughs across three areas: business scale, financial strength, and global innovation. We successfully upgraded our strategy from an oncology-focused leader to a 'dual-engine growth model' driven by oncology and general biomedicine portfolio. Encouragingly, we delivered our first full year of net profit, marking a formal entry into an era of sustainable profitability. Our robust cash reserves and positive operating cash flow will provide strong support for strategic growth. On the innovation front, three global high-potential assets advanced into or near global registrational clinical development, targeting a combined addressable market value of over US$60 billion. Meanwhile, we accelerated the global value realization of our pipeline through multiple landmark strategic collaborations, laying a solid foundation for global expansion. Total deal value reached over US$22 billion in the past year, accounting for more than 10% of China's innovative pharmaceutical sector outbound licensing value in 2025[1]. These achievements not only validate the foresight of our strategy but also highlight our uniqueness of strong growth and high certainty within China's biopharma industry. Guided by our Vision 2030 to become a global premier biopharmaceutical company, we will continue to drive progress across four core pillars: revenue, profitability, innovative pipeline and organizational capabilities, creating sustainable value for patients, shareholders and society." Revenue Set New Height, Achieved Full-Year Profitability with Strong Cash Position Total revenue reached RMB 13.0 billion, representing a year-on-year increase of 38.4%. Product revenue amounted to RMB 11.9 billion, up 44.6% year-on-year. From the commercial launch of its first product in 2019 to 18 approved products and surpassing RMB 10 billion revenue milestone, Innovent accomplished this in only 7 years, setting a new growth benchmark for China's innovative biopharmaceutical industry. The Company achieved its first full year of net profit. IFRS net profit reached RMB 814 million, and Non-IFRS net profit rose to RMB 1.72 billion, marking a structural inflection in profitability and entry into a sustainable earnings era. Operating efficiency continued to improve. Gross margin improved 2.3 percentage points to 87.2%. Selling and administrative expense ratio declined 2.9 percentage points to 48.0%. EBITDA surged to RMB 1.99 billion (2024: RMB 412 million). As of December 31, 2025, cash reserves totaled RMB 24.3 billion (~US$3.5 billion). Additionally, the Company also generated positive operating cash flow, providing strong financial support for long-term development. [2] Dual-Engine Strategy Fully Implemented, Commercial Foundation Strengthened China Leading Oncology Brand with Synergistic Value of Innovative Portfolio Innovent has established a leading oncology brand in China. Cornerstone products including TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and HALPRYZA® (rituximab injection) have benefited millions of Chinese cancer patients. In addition, five small-molecule targeted oncology drugs—Limertinib (EGFR TKI), DOVBLERON® (Taletrectinib, ROS1i), Dupert® (fulzerasib, KRAS G12Ci), JAYPIRCA® (Pirtobrutinib, BTKi), and Retsevmo® (selpercatinib, RETi) — were successfully included in the 2025 National Reimbursement Drug List (NRDL), further strengthening the competitiveness and commercial performance of Innovent's oncology portfolio. General Biomedicine Franchise Emerged as a New Growth Engine Benefiting from forward-looking strategic layout, Innovent's general biomedicine portfolio delivered strong momentum in 2025. SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025. Within a single year, the general biomedicine portfolio has become a second core engine driving high-speed growth. Today, Innovent possesses one of the highest-quality commercial portfolio and pipeline in the industry, supported by a fully established commercial network, reinforcing its solid commercial foundation. Year of Globalization: Pipeline Value Unlocked, Growth Potential Expanded 2025 marked a breakthrough year for the Company's globalization strategy, unlocking substantial long-term growth potential. Innovent successfully advanced three core assets into or near global Phase 3 clinical trials. According to its partner estimates, these late-stage assets target a combined total addressable market (TAM) of over US$60 billion, including: IBI363 (PD-1/IL-2α-bias): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications In collaboration with Takeda, IBI363 is being advanced globally. The first global MRCT Phase 3 in IO-resistant squamous NSCLC has been initiated. PoC in IO-resistant non-squamous NSCLC is completed, with a new global Phase 3 planned subject to the PoC results and regulatory communications. A Phase 3 trial in 3L colorectal cancer (CRC) in China is planned for 2026. A Phase 2 trial in IO-naïve mucosal/acral melanoma is underway in China. PoC studies in 1L NSCLC and 1L CRC are ongoing. IBI343 (CLDN18.2 ADC): Cornerstone for gastrointestinal cancers, potential TAM over US$8 billion Interim analysis from the China-Japan Phase 3 clinical trial in 3L gastric cancer is expected in 2026. Phase 3 in 3L pancreatic cancer in China was initiated in 2025. PoC studies in 1L gastric and 1L pancreatic cancer are ongoing. IBI324 (VEGF/ANG2): Potential best-in-class retinaltherapy, potential TAM US$15 billion Our partner Ollin Biosciences reported positive top-line results from the Phase 1b JADE head-to-head study against faricimab in wAMD and DME patients in the US. Innovent is working closely with Ollin to engage global regulators in 2026 and advance IBI324 into global Phase 3 trials. Diversified Partnerships to Accelerate Global Innovation Total deal value from Innovent's global collaborations reached over US$22 billion in 2025, representing over 10% of China's innovative pharma outbound licensing value. These partnerships not only accelerate global pipeline development but also help build core capabilities for Innovent to become a truly world-class biopharma. With Takeda: Landmark "IO + ADC" collaboration under a co-development and co-commercialization ("Co-Co") model for IBI363 to build its global R&D and commercialization capabilities. With Eli Lilly: Seventh partnership with an end-to-end innovation model to jointly develop novel oncology and immunology molecules, enhancing full lifecycle R&D frameworks and decision-making from a multinational perspective. With Roche: Leveraging global oncology resources to advance IBI3009 (DLL3 ADC) worldwide. With Ollin: Utilizing global ophthalmology expertise to accelerate IBI324's clinical development and market positioning. High-Quality Manufacturing Standards Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Site 1 houses 60,000 liters of antibody capacity and ADC commercial lines; Site 2 has 80,000 liters of antibody capacity, supporting global supply and CDMO services. Sustainable Development and ESG Commitment 8,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou. Over 3,000 new cancer patients initiate Innovent therapies daily; more than 6 million patients have benefited to date. Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry. First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status). Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management. Published patient education materials on thyroid eye disease and weight management to enhance public health awareness. Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 3.6 billion. Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise". Created over 2,200 jobs for new graduates. Cumulative taxes and contributions exceeding RMB 6 billion. Vision 2030: From China Leader to Global Premier Biopharma Entering 2026, Innovent celebrates its 15th anniversary. Building on its strong foundation, the Company reaffirms Vision 2030: to evolve into a global premier biopharmaceutical company. Revenue: Target RMB 20 billion by 2027 with continued expansion thereafter. International revenue will become a new growth driver in the future. Profitability: Maintain high-quality growth while steadily improving profit margins benchmarking industry-leading levels. Pipeline: Focus on advancing high-value assets including IBI363, IBI343 and IBI324. Push next-generation oncology and general biomedicine molecules into global early-stage and PoC studies. Target at least 5 molecules in global MRCT Phase 3 by 2030. Organization: Established a US R&D and operating team of nearly 100 people. Through deep partnerships with Takeda, Lilly, Ollin, Roche and others, Innovent is rapidly building global R&D, regulatory and commercial capabilities. These growing global competencies will further support independent development, enabling Innovent to leap forward into a fully independent, world-class biopharmaceutical enterprise. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Ramucirumab (Cyramza)，Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. SOURCE Innovent Biologics 21% more press release views with Request a Demo

Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC , March 3, 2026 /PRNewswire/ --The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035, as immunotherapy continues to reshape the standard of care across solid tumors and hematologic cancers [1] . Cancer drug revenues alone are expected to reach $335.2 billion by 2033, driven by the rapid clinical adoption of targeted therapies, checkpoint inhibitors, and next-generation cell therapies [2] . Companies advancing breakthrough oncology pipelines across multiple indications include Oncolytics Biotech (NASDAQ: ONCY), Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Arcellx (NASDAQ: ACLX), and Merck (NYSE: MRK). The immuno-oncology segment is forecast to expand from $65.22 billion in 2025 to $170.19 billion by 2032 at a compound annual growth rate of 14.9%, driven by rising cancer prevalence and a wave of combination therapy approvals [3] . Immunotherapy drug development remains the fastest-growing area of oncology R&D, with checkpoint inhibitors, cancer vaccines, and cell therapies collectively attracting record levels of clinical investment [4] . Oncolytics Biotech (NASDAQ: ONCY) has launched a study that could reshape how doctors treat one of the most stubborn forms of colorectal cancer. The company's randomized Phase 2 trial, REO 033, will evaluate pelareorep in combination with bevacizumab and FOLFIRI in second-line RAS-mutated (which includes KRAS), microsatellite-stable metastatic colorectal cancer, a patient population where current treatments offer limited benefit and new options are urgently needed. "I am honored to lead this study as I have a long track record working with pelareorep and have witnessed its ability to improve patient outcomes in a meaningful way," said Dr. Sanjay Goel, Professor of Medicine at Rutgers Cancer Institute of New Jersey . "The colorectal cancer data we recorded in the REO 022 study continues to be compelling to this day, as evidenced by the Fast Track Designation, and I hope we can generate additional exciting data in this new trial to support registration." The confidence behind REO 033 stems from compelling data generated in a previous clinical study. Pelareorep combined with bevacizumab and FOLFIRI demonstrated 27 months of overall survival and 16.6 months of progression-free survival, compared to 11.2 and 5.7 months for the standard of care. Objective response rate was 33% versus approximately 10% for the standard of care, more than tripling the benchmark in a notoriously difficult-to-treat population. Notably, this treatment regimen was granted Fast Track Designation by the FDA earlier this year. "The potential to improve clinical outcomes compared to the standard of care in the second-line setting would have the potential to benefit patients around the world who are affected by colorectal cancer," said Dr. Van Morris, Associate Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center . "An immunotherapy with the potential to improve outcomes would improve treatment options in colorectal cancer and would be highly welcomed, especially as we are seeing more and more patients being diagnosed with colorectal cancer." The global market for second-line treatment in KRAS-mutant, microsatellite-stable metastatic colorectal cancer runs between $3-5 billion annually . The study will randomize 60 patients to either the pelareorep combination or a control arm of bevacizumab and FOLFIRI, with objective response rate as the primary endpoint. Oncolytics expects to open the first study site later this month, with additional clinical sites added in quick succession, and preliminary data is expected by year-end 2026. CONTINUED… Read this and more news for Oncolytics Biotech at: In other industry developments: Eli Lilly (NYSE: LLY) has reported results showing substantial event-free survival benefit for Retevmo (selpercatinib) as an adjuvant therapy in early-stage RET fusion-positive lung cancer, expanding the role of targeted therapy in oncology. The LIBRETTO-432 trial enrolled 151 patients across a global, multicenter study, generating one of the largest datasets ever assembled for adjuvant targeted therapy in this setting. "We have consistently observed that cancer medicines can deliver their greatest impact when administered early in the course of a patient's treatment journey," said Jacob Van Naarden, Executive Vice President and President of Lilly Oncology. "The LIBRETTO-432 results support this observation, demonstrating an effect size in line with the most striking data for targeted adjuvant therapy in lung cancer." Lilly's breast cancer drug Verzenio (abemaciclib) generated $5.3 billion in full-year 2025 revenue, an 8% increase year over year, reinforcing the company's position as a leader in targeted oncology therapeutics. The Retevmo adjuvant data further strengthens a pipeline spanning solid tumors, hematologic cancers, and novel modalities. Gilead Sciences (NASDAQ: GILD) has agreed to acquire Arcellx (NASDAQ: ACLX) in a $7.8 billion transaction to maximize the long-term potential of anito-cel, a next-generation CAR-T cell therapy for relapsed or refractory multiple myeloma. The FDA has accepted the anito-cel BLA for review, with a potential launch later this year that would add a second CAR-T product to Gilead's oncology portfolio alongside Yescarta. "This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma," said Daniel O'Day, Chairman and CEO of Gilead Sciences . "Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy." The acquisition underscores the accelerating consolidation in cell therapy, where large-cap oncology companies are paying premium valuations for differentiated platforms with near-term regulatory catalysts. Gilead's combined cell therapy franchise, anchored by Yescarta and now anito-cel, positions the company as one of the largest players in the rapidly expanding CAR-T market. Merck (NYSE: MRK) has presented new data at the 2026 ASCO GU Cancers Symposium demonstrating that Keytruda in combination with Padcev significantly improved event-free survival, overall survival, and pathologic complete response in muscle-invasive bladder cancer. The KEYNOTE-B15 results represent the latest expansion of Keytruda's genitourinary oncology portfolio. "We're excited to share new results from our portfolio and pipeline for more patients with certain types of bladder and kidney cancers," said Dr. Marjorie Green, Senior Vice President and Head of Oncology, Global Clinical Development at Merck Research Laboratories. "The results we're presenting at ASCO GU underscore our leadership across the genitourinary cancer landscape and our commitment to advance standards of care for these patients." Merck's Keytruda franchise generated over $31 billion in global sales in 2025, maintaining its position as the world's top-selling oncology drug. The company is advancing clinical trials across virtually every major solid tumor type, including ongoing studies in colorectal and gastrointestinal cancers where immunotherapy combinations are showing increasing promise. CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES: Logo - View original content to download multimedia: